# An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM

> **NCT06116968** · PHASE3 · COMPLETED · sponsor: **Corxel Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Obstructive Hypertrophic Cardiomyopathy

## Interventions

- **DRUG:** Aficamten

## Key facts

- **NCT ID:** NCT06116968
- **Lead sponsor:** Corxel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-14
- **Primary completion:** 2025-10-20
- **Final completion:** 2025-10-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06116968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06116968, "An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06116968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*